Biorestorative Therapies, Inc. (BRTX)
NASDAQ:BRTX
Want to see BRTX full AI Analyst Report?
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.47
▼(-60.42% Downside)
Action:Reiterated
Date:05/30/26
The score is held down primarily by very weak financial performance—minimal and shrinking revenue, extreme losses, and substantial cash burn—despite low debt. Technicals provide some support from a strong recent move (price above key short-term averages and positive MACD), but the setup looks stretched (RSI > 80) and still weak versus the 200-day trend. Corporate actions increase financing flexibility but raise dilution risk, limiting the overall attractiveness.
Positive Factors
Low Leverage
An effectively debt-free balance sheet reduces interest burden and financial distress risk. For a clinical-stage biotech with variable cash flows, low leverage preserves flexibility to access equity or partner capital without fixed debt servicing, supporting durable runway options.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow near -$12M TTM versus negligible revenues creates structural funding reliance. Without revenue scale or non-dilutive partnerships, continued burn requires external financing, raising dilution risk and constraining strategic choices over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
An effectively debt-free balance sheet reduces interest burden and financial distress risk. For a clinical-stage biotech with variable cash flows, low leverage preserves flexibility to access equity or partner capital without fixed debt servicing, supporting durable runway options.
Read all positive factors
BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.18M
Dividend YieldN/A
Average Volume (3M)20.51M
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-8.47%
EPS Growth25.61%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume59,302,091
30 Day Avg. Volume20,509,498
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue3.31
Enterprise Value/Gross Profit3.60
Enterprise Value/Ebitda-0.09
Forecast
1Y Price Target
$8.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.90M
BioRestorative Therapies Business Overview & Revenue Model
Company Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs...
How the Company Makes Money
null...
BioRestorative Therapies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.Positive Updates
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Negative Updates
Significant Revenue Decline
Third-quarter 2025 revenues were $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to the timing of orders for the developing biocosmeceutical revenue stream.
Read all updates
Q3-2025 Updates
Positive
Negative
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Read all positive updates
Company Guidance
In the third quarter of 2025, BioRestorative Therapies reported a mixed financial performance, with revenues significantly declining to approximately $11,800 from $233,600 in the same period of 2024, primarily due to timing in the biocosmeceutical revenue stream. The company reported a loss from operations of $3.7 million, up from $2.3 million in the previous year, and a net loss of $3 million or $0.33 per share, compared to a net loss of $1 million or $0.13 per share in 2024. Despite these financial challenges, BioRestorative Therapies ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities, excluding $1.1 million from recent financing. On the clinical front, the company is advancing its Phase II BRTX-100 study for chronic lumbar disc disease, with enrollment nearing completion and a potential Type B FDA meeting anticipated. The company also highlighted substantial progress in its ThermoStem program targeting obesity, while continuing discussions for a potential licensing agreement. The biocosmeceuticals business shows promise, with strategic leadership changes and a focus on expanding distribution channels, although revenue guidance remains uncertain.BioRestorative Therapies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 357.87K | 359.70K | 401.00K | 145.80K | 119.80K | 46.00K |
| Gross Profit | 329.55K | 335.86K | 372.93K | 145.80K | 119.80K | 46.00K |
| EBITDA | -13.42M | -15.44M | -11.37M | -14.97M | -18.74M | -26.22M |
| Net Income | -11.06M | -14.24M | -8.98M | -10.42M | -13.22M | -44.30M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 2.95M | 10.73M | 11.07M | 14.75M | 21.03M |
| Total Debt | 0.00 | 0.00 | 0.00 | 162.32K | 301.64K | 670.70K |
| Total Liabilities | 1.61M | 3.72M | 3.75M | 2.61M | 6.14M | 856.50K |
| Stockholders Equity | 3.03M | 356.74K | 8.53M | 10.00M | 10.29M | 21.60M |
Cash Flow | ||||||
| Free Cash Flow | -11.90M | -10.91M | -8.34M | -6.60M | -6.35M | -3.36M |
| Operating Cash Flow | -11.82M | -10.79M | -8.23M | -6.43M | -5.91M | -3.33M |
| Investing Cash Flow | 7.50M | 8.90M | 514.53K | 3.25M | -13.40M | -30.66K |
| Financing Cash Flow | 6.20M | 2.85M | 7.38M | 2.35M | 0.00 | 21.32M |
BioRestorative Therapies Technical Analysis
Positive
1.18
Price Trends
0.25
Positive
0.47
Positive
0.93
Negative
Market Momentum
0.04
Negative
82.69
Negative
58.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Positive. The current price of 1.18 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.25, and above the 200-day MA of 0.93, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 82.69 is Negative, neither overbought nor oversold. The STOCH value of 58.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRTX.
BioRestorative Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $25.09M | -0.64 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $12.18M | -0.39 | -423.84% | ― | -8.47% | 25.61% | |
44 Neutral | $26.18M | -2.78 | >-0.01% | ― | -43.86% | 49.21% | |
44 Neutral | $15.44M | -1.75 | -94.94% | ― | ― | 53.06% | |
43 Neutral | $28.37M | -0.15 | -83.59% | ― | ― | 19.36% | |
42 Neutral | $19.91M | -0.15 | 0.02% | ― | ― | -101.45% |
* Healthcare Sector Average
BRTX
BioRestorative Therapies
0.48
-1.32
-73.44%
CLRB
Cellectar Biosciences
3.14
-4.72
-60.05%
MRKR
Marker Therapeutics
1.57
0.16
11.35%
COCP
Cocrystal Pharma
1.12
-0.53
-32.12%
SNSE
Sensei Biotherapeutics
21.14
14.84
235.34%
AEON
AEON Biopharma
0.76
0.21
37.45%
BioRestorative Therapies Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
BioRestorative Therapies Extends Executive Leadership Employment Agreements
Positive
May 29, 2026
On May 27, 2026, BioRestorative Therapies, Inc. signed new employment agreements with President, Chief Executive Officer and Chairman Lance Alstodt and Chief Financial Officer Robert Kristal, extending their terms through May 27, 2029 while keepin...
Executive/Board Changes
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives
Positive
May 1, 2026
On May 1, 2026, BioRestorative Therapies, Inc.’s compensation committee approved discretionary cash bonuses for its named executive officers for services rendered in 2025, reflecting increases over the prior year in both salary and equity-ba...
Business Operations and StrategyRegulatory Filings and Compliance
BioRestorative Therapies Updates Corporate Presentation for Investors
Neutral
Apr 23, 2026
On April 23, 2026, BioRestorative Therapies, Inc. released an updated corporate presentation intended for use at conferences and investor meetings, making it available on its website. The company emphasized that the information is being furnished ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.